A new biotech born from Jazz Pharmaceuticals' acquisition deal is betting that rare disease genetics can unlock treatments ...
BioMarin has agreed to pay $70 million upfront for Fabry disease therapy from GC Biopharma and Hanmi Pharm. At the center of ...
Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.
Hematology research now needs new evidence strategies as targeted therapies create smaller, more specialized patient groups ...
New ICER and PHIL data show drug launch prices soaring while patients, especially on Medicare, struggle to access needed care ...
Flagship has merged 3 of its own portfolio companies into a single powerhouse aimed at predicting how drugs will work before ...
Dren Bio has closed an oversubscribed $350 million private financing round to advance its lead antibody candidate toward ...
Intellectual property enforcement in the life sciences sector is evolving rapidly overall, and in no small part due to ...
Recent court rulings and USPTO guidance reshape how biotech startups should approach patent strategy for drugs and ...
EUCROF says the upcoming Ukrainian CRO Association will help show the country remains a strong location for drug trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results